NFKBIB

NFKBIB (IκBβ) is a cytoplasmic inhibitor of NF-κB signaling that, distinct from a generic NF-κB brake, is selectively required for the LPS-induced expression of a defined subset of pro-inflammatory genes — IL1β, IL6, and IL12β — acting through its NF-κB subunit binding partner cRel rather than through global NF-κB suppression (PMID:25908863). Its activity is set by regulated degradation: low-dose NF-κB inhibitors specifically attenuate LPS-induced IκBβ degradation and the resulting cytokine output, and IκBβ overexpression dampens LPS-driven signaling in vivo (PMID:25908863). Across epithelial and tumor contexts NFKBIB behaves as a restraint on NF-κB, and its loss activates the pathway: it suppresses influenza A virus replication via NF-κB modulation (PMID:28448456), acts as a tumor suppressor in nasopharyngeal carcinoma where it limits migration, angiogenesis, and pro-angiogenic gene expression (PMID:26227166), and physically interacts with TSPAN1 to prevent NF-κB overactivation and metastasis (PMID:38135697). NFKBIB levels are controlled at multiple regulatory layers — direct post-transcriptional targeting by miR-20a and miR-4776, which lowers IκBβ protein and de-represses NF-κB to drive chemoresistance and viral replication (PMID:26286834, PMID:28448456); transcriptional induction by nuclear KIT binding its promoter to form a KIT→NFKBIB→RELA→KIT autoregulatory loop in imatinib-resistant GISTs (PMID:31363162); and epigenetic silencing through LINC01578-mediated recruitment of EZH2 to its promoter, activating NF-κB to promote colon cancer metastasis (PMID:33040438). At the organismal level, compound IκB loss including Nfkbib drives myeloid-biased hematopoiesis via both progenitor expansion and microenvironmental effects (PMID:39791596).

1. 1995 Low

   Before any inflammatory role was known, NFKBIB was first captured as a thyroid-hormone-receptor-interacting protein, an early but isolated lead on its protein-interaction behavior.

   Evidence Yeast two-hybrid interaction trap with LexA fusion reporter assay, isolating NFKBIB as TRIP9 binding TRβ ligand-binding domain

   PMID:7776974

   Open questions at the time

   • Single yeast two-hybrid with no biochemical reconstitution in mammalian cells
   • Relationship of this TR interaction to NF-κB inhibition never established
   • No follow-up confirming functional relevance
2. 2003 Low

   The question of whether IκBβ acts only as a cytoplasmic sequestrant was addressed by showing distinct isoform behavior, with a nuclear-localized isoform implicated in sustaining rather than terminating NF-κB transcription.

   Evidence Western blot, subcellular fractionation and quantitative protein analysis of IκBβ isoforms in IL-1β-stimulated human amnion

   PMID:12651903

   Open questions at the time

   • Nuclear role inferred from localization, not functional manipulation
   • Isoform-specific functions not dissected genetically
   • No direct demonstration of NF-κB protection
3. 2015 High

   The central mechanistic advance defined IκBβ not as a generic inhibitor but as a selective, cRel-dependent requirement for a specific LPS-induced pro-inflammatory gene module.

   Evidence Transgenic overexpressing mice, genetic KO/siRNA, pharmacological NF-κB inhibition, and a cRel-NLS cell-permeable peptide with cytokine readout in macrophages and fibroblasts

   PMID:25908863

   Open questions at the time

   • Molecular basis of gene-subset selectivity not fully resolved
   • Structural detail of IκBβ–cRel complex absent
   • Degradation kinetics under different stimuli not mapped
4. 2015 Medium

   Post-transcriptional control of NFKBIB was established by showing a microRNA directly tunes IκBβ protein to set NF-κB output and chemoresistance.

   Evidence 3'UTR luciferase reporter, ago-immunoprecipitation, miRNA mimic/inhibitor, Western blot and apoptosis assays in gastric cancer cells (miR-20a)

   PMID:26286834

   Open questions at the time

   • Downstream livin/survivin link correlative
   • Single lab, single cancer context
   • In vivo relevance not tested
5. 2015 Medium

   NFKBIB was placed as a tumor suppressor whose restoration suppresses NF-κB-driven migration and angiogenesis, broadening its role beyond inflammation.

   Evidence Microcell-mediated chromosome transfer, functional complementation, migration/angiogenesis/tumor-formation assays and gene expression in nasopharyngeal carcinoma

   PMID:26227166

   Open questions at the time

   • Akt/GSK3β crosstalk proposed from expression data, not mechanism
   • Direct molecular target of suppression unclear
   • Single lab
6. 2017 Medium

   A second microRNA axis confirmed direct post-transcriptional silencing of NFKBIB and tied it to antiviral defense, with IκBβ restraining viral replication via NF-κB.

   Evidence Ago-immunoprecipitation, 3'UTR luciferase, miRNA mimic, NFKBIB overexpression and viral-load measurement in IAV-infected bronchial epithelial cells (miR-4776)

   PMID:28448456

   Open questions at the time

   • Which NF-κB-dependent antiviral effectors mediate restraint unspecified
   • Single cell system
   • miR-4776 induction mechanism not defined
7. 2019 High

   Transcriptional regulation of NFKBIB was uncovered as part of an autoregulatory circuit, showing nuclear KIT directly induces the NFKBIB promoter to constrain RELA in drug-resistant GIST.

   Evidence ChIP-seq, ChIP assay, siRNA knockdown, RELA overexpression, promoter-reporter and xenograft in imatinib-resistant gastrointestinal stromal tumors

   PMID:31363162

   Open questions at the time

   • Generality of the KIT→NFKBIB→RELA→KIT loop beyond GIST untested
   • Direct KIT-NFKBIB promoter contact site not mapped at base resolution
8. 2020 Medium

   Epigenetic silencing emerged as a third regulatory layer, with a chromatin-bound lncRNA recruiting EZH2 to repress NFKBIB and unleash NF-κB-driven metastasis.

   Evidence ChIP, RNA pulldown, promoter reporter, siRNA/overexpression and in vivo metastasis model in colon cancer (LINC01578/EZH2)

   PMID:33040438

   Open questions at the time

   • Histone mark deposition at NFKBIB promoter not directly profiled
   • Generalizability beyond colon cancer untested
   • Single lab
9. 2021 Medium

   Compound IκB genetics placed NFKBIB loss in hematopoietic regulation, showing elevated NF-κB drives myeloid bias through both progenitor expansion and the bone marrow microenvironment.

   Evidence Nfkbia+/-Nfkbib-/-Nfkbie-/- mouse model with scRNA-seq, population dynamics modeling and bone marrow transplantation

   PMID:39791596

   Open questions at the time

   • NFKBIB contribution inferred from compound knockout, not isolated
   • Cell-autonomous vs microenvironmental contributions of NFKBIB specifically not separated
10. 2023 Low

    A direct protein partner restraining NF-κB was identified, with TSPAN1 binding IκBβ to prevent pathway overactivation and metastasis.

    Evidence Co-immunoprecipitation, migration/invasion assays, in vivo metastasis assay and NF-κB pathway analysis in nasopharyngeal carcinoma

    PMID:38135697

    Open questions at the time

    • Single Co-IP without reciprocal validation or structural mapping
    • Mechanism of how TSPAN1 binding affects IκBβ activity unresolved
    • Single lab

• How the multiple regulatory layers (degradation, miRNA, transcriptional, epigenetic, protein interaction) are integrated to set IκBβ levels in a given cell, and the structural basis for its cRel-selective gene control, remain unresolved.
• No structural model of IκBβ–cRel selectivity
• No unified model coupling NFKBIB transcriptional and post-transcriptional control
• Isoform-specific nuclear function not mechanistically dissected